Ignacy Ilski

Mr. Ignacy Ilski

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KŻKacper Żełabowski
Kacper Żełabowski
WPWiktor Manuel Petrov
Wiktor Manuel Petrov
DŚDawid Ślebioda
Dawid Ślebioda
MRMalwina Rusinek
Malwina Rusinek
KBKamil Biedka
Kamil Biedka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder generally associated with pediatric patients and in lesser extent with adults. Patients diagnosed with ADHD have a higher likelihood of developing addiction. Consequently, a disorder that frequently co-occurs with ADHD is Substance Use Disorder (SUD). The pharmaceuticals prescribed in the treatment of ADHD are predominantly stimulants, such as methylphenidate and amphetamines, which possess a high addiction potential. The objective of this study is to examine the risk of developing substance dependence during stimulant treatment in individuals with ADHD who have a natural predisposition to addiction, with particular emphasis on adult patients with a history of SUD. Our literature review was conducted using research papers from PubMed, Google Scholar, Embase, ProQuest and ScienceDirect. The main results from our review are as follows: (i) the majority of studies indicate that the administration of stimulants in the treatment of ADHD does not increase the risk of developing Substance Use Disorder; (ii) stimulants may also be used in the treatment of SUD; (iii) while pharmacotherapy is a crucial part of ADHD treatment, a holistic approach comprising pharmacological and non-pharmacological therapy is most effective; (iv) holistic management of ADHD is necessary to improve patients’ quality of life to the greatest extent possible.

16 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KŻKacper Żełabowski
Kacper Żełabowski
KBKamil Biedka
Kamil Biedka
WPWojciech Pichowicz
Wojciech Pichowicz
MSMaria Sterkowicz
Maria Sterkowicz
IRIzabela Radzka
Izabela Radzka
ACAgnieszka Chłopaś-Konowałek
Agnieszka Chłopaś-Konowałek
Background: Driving is a coordinated psychomotor activity that involves reaction time, attention, and decision-making. Psychoactive substances such as 2-phenylethylamine (PEA) derivatives and opioids may affect these functions and contribute to traffic safety. This systematic review revealed the effects of the selected PEA derivatives and opioids on psychomotor performance among drivers and potential road safety outcomes. Methods: The review followed PRISMA 2020 standards. Using the PICO method, we conducted a systematic search in Embase, PubMed, and Web of Science (2000–2025). Included studies involved adult participants and quantified the effect of PEA derivatives or opioids on driving-related psychomotor function. Thirty-one articles, such as randomized controlled trials, crossover studies, observational studies, and simulator-based studies, were examined. Risk of bias was evaluated using the RoB2 tool. Results: Evidence indicates therapeutic amphetamine and methylphenidate doses can enhance psychomotor function and safety in patients with ADHD. Recreational or high-dose use of methamphetamine and MDMA is associated with impaired coordination, variable speed, and increased impulsivity. Opioid effects are tolerance- and dose-dependent. Small therapeutic doses of fentanyl in chronically treated patients do not notably impair driving. On the other hand, methadone and tramadol commonly cause somnolence, retardation of reaction, and increased accident risk. Conclusions: The impact of opioids and PEA derivatives on psychomotor function is multifactorial, depending on dose, time, route of administration, and patient status. These substances can either improve or impair driving safety. The findings confirm the need for individual-specific pharmacotherapy treatment. They also highlight the importance of further studies to formulate evidence-based clinical and legislative guidelines.

6 June 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
RKRozalia Beata Kozińska
Rozalia Beata Kozińska
JŚJulia Karolina Ślęzak
Julia Karolina Ślęzak
IIIgnacy Ilski
Ignacy Ilski
MPMaja Ewa Podsiadła
Maja Ewa Podsiadła
KBKamil Biedka
Kamil Biedka
EKEmilia Królewicz
Emilia Królewicz
Opioids comprise a class of substances characterized by a narrow therapeutic window and significant euphoric effects. Opioid-related mortality remains a critical global health issue, primarily resulting from respiratory depression associated with full μ-opioid receptor agonists. Buprenorphine is distinguished by its pharmacological profile as a partial μ-opioid receptor agonist, exhibiting a ceiling effect on both respiratory depression and euphoria. These characteristics render buprenorphine particularly valuable in opioid replacement therapy for opioid use disorder and in the management of both chronic and acute pain. Current literature indicates that, due to these properties, buprenorphine possesses a superior safety profile compared to other opioids. This narrative review evaluates whether buprenorphine can cause fatal overdose despite its protective ceiling effect and examines cases of buprenorphine-related fatalities. The review synthesizes data from pre-clinical, clinical, pharmacological, and toxicological studies. Current literature supports the consensus that the established ceiling effect on respiratory depression does not fully eliminate the risk of fatal overdose. Polysubstance use, particularly co-ingestion of other central nervous system depressants, significantly increases this risk, and most buprenorphine-related deaths involve such combinations. Additionally, buprenorphine’s safety is reduced in vulnerable populations, including opioid-naive individuals, children, and patients with pre-existing respiratory compromise. While buprenorphine alone presents a substantially lower fatality risk compared to other opioids, the ceiling effect is pharmacodynamic rather than absolute, and toxicity or fatal overdose may still occur. Current data gathered from clinical and pre-clinical studies suggest that buprenorphine is safer than full μ-opioid receptor agonists, but it is not without risk. The ceiling effect’s protective benefits depend on context. Therefore, despite its improved safety profile, buprenorphine should not be regarded as risk-free.

11 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MNMaciej Nowicki
Maciej Nowicki
IIIgnacy Ilski
Ignacy Ilski
JŻJan Żywica
Jan Żywica
ISIgor Szczurek
Igor Szczurek
MSMagdalena Szydłowicz
Magdalena Szydłowicz
Mariusz ChabowskiMariusz Chabowski
Mariusz Chabowski
Background/Objectives: Pneumocystis jirovecii colonization induces persistent low-grade pulmonary inflammation, which may alter fluorodeoxyglucose (FDG) uptake in positron emission tomography/computed tomography (PET/CT). We aimed to evaluate whether asymptomatic infection influences the maximum standardized uptake value (SUVmax) or clinicopathological parameters of primary lung cancer. Methods: In this prospective single-center observational study, 107 consecutive patients undergoing surgical resection for primary lung cancer were enrolled. Preoperative FDG PET/CT scans were obtained within four weeks prior to surgery. Intraoperative respiratory secretions and lung tissue samples were analyzed for P. jirovecii, using nested polymerase chain reaction (nested-PCR) targeting the mitochondrial large subunit rRNA gene. Propensity score matching (PSM) adjusting for age, sex, and body mass index was performed across 1:1, 1:2, and 1:3 matching models. Results: Pneumocystis jirovecii colonization was confirmed in 12 of 107 patients (11.21%). In the unadjusted cohort, no significant differences in primary lesion SUVmax were identified between positive and negative patients (10.38 ± 6.50 vs. 8.86 ± 6.58, p = 0.411), nor across matched models (1:1: p = 0.555; 1:2: p = 0.951; 1:3: p = 0.926). Following PSM, patients without colonization exhibited significantly larger maximum tumor diameters in both 1:2 (30.71 ± 19.23 vs. 18.25 ± 6.63 mm, p = 0.035) and 1:3 matching models (29.08 ± 17.47 vs. 18.25 ± 6.63 mm, p = 0.035). Conclusions: We did not find any association between P. jirovecii colonization and preoperative metabolic tumor staging on FDG PET/CT. However, asymptomatic carriage was associated with smaller primary tumor dimensions following propensity adjustment in 1:2 and 1:3 matching models, warranting further exploration of host–fungal interactions within the pulmonary tumor microenvironment.